Table 5.
Highest paying companies.
| Company | Total general payments (US $) | Manufactured products |
| Abbvie | 7,365,101.61 | Adalimumab (Humira), risankizumab (Skyrizi), upadacitinib (Rinvoq) |
| Galderma | 7,302,686.12 | Hyaluronic acid gel filler (Restylane), abobotulinumtoxina (Dysport), poly-L-lactic acid filler (Sculptra), ivermectin cream (Soolantra), brimonidine topical gel (Mirvaso), adapalene and benzoyl peroxide (Epiduo) |
| Allergan (subsidiary of Abbvie) | 5,993,810.99 | Cross-linked hyaluronic acid filler (Juvederm), deoxycholic acid (Kybella), onabotulinumtoxina (Botox), cryolipolysis (Coolsculpting) |
| Bausch (Ortho dermatologics) | 5,342,108.74 | Brodalumab (Siliq), laser devices (via Solta) |
| Celgene | 4,938,532.20 | Apremilast (Otezla; sold in 2019) |
| Lilly | 4,295,681.28 | Ixekizumab (Taltz) |
| Regeneron | 3,835,317.28 | Dupilimab (Dupixent) |
| Novartis | 3,599,007.79 | Secukinumab (Cosentyx), ruxolitinib (Jakafi), omalizumab (Xolair) |
| Pfizer | 3,435,221.32 | Etanercept (Enbrel), tofacitinib (Xeljanz) |
| Genzyme | 2,670,075.41 | Dupilimab (Dupixent) |
| Janssen | 2,500,056.99 | Golimumab (Simponi), infliximab (Remicade), ustekinumab (Stelara), guselkumab (Tremfya) |
| Merz pharmaceuticals | 2,232,056.79 | Incobotulinumtoxina (Xeomin), calcium hydroxylapatite gel filler (Radiesse), hyaluronic acid filler (Belotero), intense focused ultrasound (Ultherapy), polidocanol (Asclera) |
| Leo pharma | 1,967,161.84 | Azelaic acid gel (Finacea), tacrolimus ointment (Protopic), topical vitamin D analogues |
| Almirall | 1,938,517.92 | Sarecycline (Seysara), dapsone gel (Aczone) |
| Bayer | 1,521,718.32 | Clotrimazole |
| Genentech | 1,489,473.68 | Vismodegib (Erivedge), rituximab (Rituxan), omalizumab (Xolair) |
| Amgen | 1,276,055.07 | Etanercept (Enbrel), apremilast (Otezla) |
| Sensus | 1,071,990.39 | Laser devices |
| Promius (subsidiary of Dr. Reddy's Laboratories) | 1,012,017.41 | Topical corticosteroids |
| Sun Pharma | 987,798.76 | Tildrakizumab-asmn (Ilumya) |